PTC Therapeutics, Inc. (PTCT) — Financial statements
Income statement, balance sheet, and cash flow for PTC Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,731↑114.5% | 807↓14.0% | 938↑34.2% | 699↑29.7% | 539 | |
| Cost of Revenue | 72↑25.0% | 57↓12.4% | 65↑46.6% | 45↑38.2% | 32 | |
| Gross Profit | 1,659↑121.4% | 749↓14.1% | 872↑33.4% | 654↑29.2% | 506 | |
| Operating Expenses | ||||||
| R&D Expenses | 455↓14.8% | 534↓19.8% | 667↑2.3% | 651↑20.5% | 541 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 347↑15.4% | 301↓9.5% | 333↑2.0% | 326↑14.1% | 286 | |
| Other Expenses | 0.00↓100.0% | 217↓30.8% | 313↑152.1% | 124↑128.6% | 54 | |
| Operating Expenses | 802↓23.7% | 1,052↓19.8% | 1,312↑19.1% | 1,102↑25.1% | 881 | |
| Total Costs & Expenses | 874↓21.2% | 1,109↓19.5% | 1,377↑20.2% | 1,146↑25.5% | 913 | |
| Operating Results | ||||||
| Operating Income | 857↑383.1% | -303↑31.2% | -440↑1.8% | -447↓19.5% | -374 | |
| Depreciation & Amortization | 39↓48.7% | 76↓68.0% | 237↑83.6% | 129↑100.9% | 64 | |
| EBITDA | 888↑836.9% | -120↑63.5% | -330↑10.2% | -368↑0.1% | -368 | |
| EBIT | 849↑532.8% | -196↑65.4% | -567↓14.2% | -497↓14.9% | -432 | |
| Interest & Other Income | ||||||
| Net Interest Income | -152↑8.8% | -167↓29.3% | -129↓42.2% | -91↓5.6% | -86 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 152↓8.8% | 167↑29.3% | 129↑42.2% | 91↑5.6% | 86 | |
| Non-Operating Income | 8↑107.2% | -106↓183.5% | 127↑159.0% | 49↓15.0% | 58 | |
| Other Income / Expenses | -160↓164.1% | -61↑76.4% | -257↓83.2% | -140↑2.7% | -144 | |
| Income Before Tax | 697↑291.8% | -363↑47.8% | -696↓18.5% | -587↓13.3% | -518 | |
| Income Tax Expense | 14↑7840.3% | 0.18↑100.3% | -70↓144.1% | -28↓612.0% | 6 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 683↑287.9% | -363↑42.0% | -627↓12.1% | -559↓6.7% | -524 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 683↑287.9% | -363↑42.0% | -627↓12.1% | -559↓6.7% | -524 | |
| Bottom-Line Net Income | 683↑287.9% | -363↑42.0% | -627↓12.1% | -559↓6.7% | -524 | |
| EPS (Basic) | 8.58↑281.4% | -4.73↑43.5% | -8.37↓7.4% | -7.79↓4.8% | -7.43 | |
| EPS (Diluted) | 7.78↑264.5% | -4.73↑43.5% | -8.37↓7.4% | -7.79↓4.8% | -7.43 | |
| Weighted Average Shares | 80↑3.5% | 77↑2.7% | 75↑4.3% | 72↑1.8% | 70 | |
| Weighted Average Diluted Shares | 88↑14.9% | 77↑2.7% | 75↑4.3% | 72↑1.8% | 70 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.